Shawver Laura
Known title: Chief Executive OfficerCIK: 0001551891
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
RLAY Valuation Debate: Is the Pullback a Value Trap?. Recent analysis questions whether Relay Therapeutics is undervalued after its recent price drop or if the market has already priced in potential gains. One report suggests the stock is fully priced relative to its book value, while another asks if the current level offers a bargain. The stock is currently trading near a key support level, with analysts maintaining a higher average target price.
Transaction History
| SPRY | ▲ Buy | Option Exercise | 22,509 | $109K | 4/7/2025 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 27,493 | $133K | 4/7/2025 | View on chart |
| SPRY | ▼ Sell | Open Market | 50,002 | $615K | 4/7/2025 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 49,600 | $241K | 3/6/2025 | View on chart |
| SPRY | ▼ Sell | Open Market | 49,600 | $556K | 3/6/2025 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 400 | $2K | 3/5/2025 | View on chart |
| SPRY | ▼ Sell | Open Market | 400 | $4K | 3/5/2025 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 9,064 | $29K | 2/3/2025 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 40,936 | $199K | 2/3/2025 | View on chart |
| SPRY | ▼ Sell | Open Market | 50,000 | $616K | 2/3/2025 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 50,000 | $158K | 1/6/2025 | View on chart |
| SPRY | ▼ Sell | Open Market | 50,000 | $555K | 1/6/2025 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 14,772 | $47K | 12/4/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 14,772 | $203K | 12/4/2024 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 25,606 | $33K | 12/3/2024 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 62,378 | $196K | 12/3/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 87,984 | $1.2M | 12/3/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 901 | $13K | 12/2/2024 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 67,616 | $86K | 12/2/2024 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 29,628 | $38K | 12/2/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 96,343 | $1.3M | 12/2/2024 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 97,003 | $123K | 9/1/2023 | View on chart |
| SPRY | ▼ Sell | Open Market | 100,000 | $771K | 9/1/2023 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 2,997 | $4K | 9/1/2023 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 18,897 | $24K | 8/4/2023 | View on chart |
| SPRY | ▼ Sell | Open Market | 18,897 | $133K | 8/4/2023 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 26,107 | $33K | 8/3/2023 | View on chart |
| SPRY | ▼ Sell | Open Market | 26,107 | $183K | 8/3/2023 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 36,281 | $46K | 8/2/2023 | View on chart |
| SPRY | ▼ Sell | Open Market | 36,281 | $257K | 8/2/2023 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 18,715 | $24K | 8/1/2023 | View on chart |
| SPRY | ▼ Sell | Open Market | 18,715 | $135K | 8/1/2023 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 8,858 | $11K | 7/7/2023 | View on chart |
| SPRY | ▼ Sell | Open Market | 8,858 | $56K | 7/7/2023 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 33,510 | $43K | 7/6/2023 | View on chart |
| SPRY | ▼ Sell | Open Market | 33,510 | $213K | 7/6/2023 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 31,112 | $40K | 7/5/2023 | View on chart |
| SPRY | ▼ Sell | Open Market | 31,112 | $200K | 7/5/2023 | View on chart |
| SPRY | ▼ Sell | Open Market | 26,520 | $178K | 7/3/2023 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 26,520 | $34K | 7/3/2023 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 26,941 | $34K | 6/2/2023 | View on chart |
| SPRY | ▼ Sell | Open Market | 26,941 | $187K | 6/2/2023 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 73,059 | $93K | 6/1/2023 | View on chart |
| SPRY | ▼ Sell | Open Market | 73,059 | $497K | 6/1/2023 | View on chart |
| RLAY | ▼ Sell | Gift | 12,099 | — | 5/24/2023 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 42,900 | $54K | 5/9/2023 | View on chart |
| SPRY | ▼ Sell | Open Market | 42,900 | $228K | 5/9/2023 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 57,100 | $73K | 5/8/2023 | View on chart |
| SPRY | ▼ Sell | Open Market | 57,100 | $352K | 5/8/2023 | View on chart |
| SPRY | ▼ Sell | Open Market | 43,896 | $201K | 11/9/2022 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 78,740 | $100K | 8/5/2022 | View on chart |
| SPRY | ▲ Buy | Grant | 68,107 | $0 | 5/2/2022 | View on chart |
| SPRY | ▲ Buy | Grant | 27,500 | $0 | 2/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Aquestive news highlights biotech valuation dynamics
Recent market discussion focused on Aquestive Therapeutics and the pricing of anaphylaxis drug success. While this news does not directly involve ARS Pharmaceuticals, it reflects broader sector sentiment regarding biotech valuations. ARS Pharmaceuticals is currently trading with an RSI of 37.5, indicating mild oversold conditions relative to its recent range.
Aquestive news highlights biotech valuation dynamics. Recent market discussion focused on Aquestive Therapeutics and the pricing of anaphylaxis drug success. While this news does not directly involve ARS Pharmaceuticals, it reflects broader sector sentiment regarding biotech valuations. ARS Pharmaceuticals is currently trading with an RSI of 37.5, indicating mild oversold conditions relative to its recent range.